Effects of TA-65, a Telomerase Activator on Metabolic Syndrome

Status Completed

Clinical Trial Summary

This study is being conducted to evaluate the efficacy of TA-65, a purified extract of Astragalus root, on insulin resistance, oxidative stress, and inflammation in individuals classified with metabolic syndrome.

Clinical Trial Description

Short telomeres are strongly linked to increased risk of cardiovascular disease and diabetes, indications where tissue aging and senescence play significant roles. Shorter leukocyte telomere length has been linked to impaired glucose tolerance, Type 2 Diabetes, and coronary heart disease. Telomere length and telomerase activity have been shown to be significantly lower in CAD patients. Telomere length may play an important role in predicting cardiovascular disease and diabetes. TA-65 may not only ameliorate the symptoms associated with these disease states, but be a preventive measure as well.

In this study, the researchers will investigate whether telomerase activator (TA)-65 can also improve the metabolic dysregulations associated with metabolic syndrome including oxidative stress, inflammation, high blood pressure and dyslipidemias. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02531334
Study type	Interventional
Source	University of Connecticut
Contact
Status	Completed
Phase	N/A
Start date	August 2015
Completion date	June 2018

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02702375` - Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases	N/A
Completed	`NCT02649348` - Effects of Prehabilitation in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome	N/A
Completed	`NCT02918422` - Controlled Clinical Study to Determine Novel Health Benefits of Cheese Consumption	N/A
Completed	`NCT02459691` - Culturally-adapted Diabetes Prevention Lifestyle Intervention for Latinos (E-LITE Latinos)	N/A
Completed	`NCT02356952` - Effect of a Low Glycemic Index on Metabolic Syndrome	N/A
Completed	`NCT02337933` - Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome	Phase 2
Completed	`NCT02402985` - Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 Diabetics	N/A
Completed	`NCT01694056` - Soy Protein Intake and the Metabolic Syndrome	N/A
Completed	`NCT00344903` - Dallas Heart Study 2: Return Clinic Visit for the Dallas Heart Study Cohort	N/A
Recruiting	`NCT00408824` - Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study)	N/A
Completed	`NCT00362908` - Effects of Low and Moderate Fat Diets on Lipids, Inflammation and Vascular Reactivity in the Metabolic Syndrome	N/A
Completed	`NCT00395486` - ROMEO (Rosuvastatin in Metabolic syndrOme)	Phase 4
Completed	`NCT00140816` - Dairy Products and Metabolic Effects (Norwegian Part)	N/A
Completed	`NCT00101517` - Partnership Programs to Reduce Ethnic Differences in the Risk of Cardiovascular Disease	N/A
Completed	`NCT00455325` - Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)	Phase 2
Completed	`NCT00166036` - Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells	Phase 2
Recruiting	`NCT00177892` - Obstructive Sleep Apnea (OSA) and Metabolic Syndrome: Role of Oxidative Stress	N/A
Completed	`NCT00073775` - Epidemiology of Stress and the Metabolic Syndrome	N/A
Completed	`NCT00074451` - Genomewide Search for Loci Underlying Metabolic Syndrome
Completed	`NCT00200993` - Peripheral Effects of Exercise on Cardiovascular Health (STRRIDE I)	Phase 2